Alector Inc. (ALEC)’s Financial Results Comparing With Translate Bio Inc. (NASDAQ:TBIO)

This is therefore a contrasting of the risk, institutional ownership, analyst recommendations, profitability, dividends, earnings and valuation in Alector Inc. (NASDAQ:ALEC) and Translate Bio Inc. (NASDAQ:TBIO). The two are both Biotechnology companies that compete with one another.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Alector Inc. 17 -0.36 29.68M -0.40 0.00
Translate Bio Inc. 9 0.00 23.60M -2.44 0.00

Table 1 shows the top-line revenue, earnings per share and valuation for Alector Inc. and Translate Bio Inc.


Table 2 shows Alector Inc. and Translate Bio Inc.’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Alector Inc. 179,769,836.46% 0% 0%
Translate Bio Inc. 250,265,111.35% 0% 0%


The Current Ratio of Alector Inc. is 7.9 while its Quick Ratio stands at 7.9. The Current Ratio of rival Translate Bio Inc. is 7.7 and its Quick Ratio is has 7.7. Alector Inc. is better equipped to clear short and long-term obligations than Translate Bio Inc.

Analyst Recommendations

Alector Inc. and Translate Bio Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Alector Inc. 0 0 1 3.00
Translate Bio Inc. 0 0 0 0.00

The average target price of Alector Inc. is $28, with potential upside of 44.18%.

Insider & Institutional Ownership

Institutional investors owned 59.1% of Alector Inc. shares and 58.3% of Translate Bio Inc. shares. Insiders owned roughly 8.1% of Alector Inc.’s shares. Competitively, 31.15% are Translate Bio Inc.’s share owned by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Alector Inc. 6.24% 11.86% 7.1% 0% 0% 17.33%
Translate Bio Inc. -9.89% -33.66% -14.41% 41.7% -34.32% 6.93%

For the past year Alector Inc.’s stock price has bigger growth than Translate Bio Inc.


Alector Inc. beats on 6 of the 9 factors Translate Bio Inc.

Translate Bio, Inc., a messenger RNA therapeutics company, engages in developing medicines to treat diseases caused by protein or gene dysfunction. It is developing MRT5005 that is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 for the treatment of ornithine transcarbamylase deficiency. It has strategic alliances with Sanofi Pasteur. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.